Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
P/B ratio for Oculis Holding AG (OCS)
P/B ratio as of 2023: 3.01
According to Oculis Holding AG's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.01. At the end of 2022 the company had a P/B ratio of -3.12.
P/B ratio history for Oculis Holding AG from 2020 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 3.01 |
| 2022 | -3.12 |
| 2021 | -4.74 |
| 2020 | -6.44 |